Close Menu

Latin America

Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.

By profiling hereditary risk variants in women with breast cancer, researchers hope to lay the foundation for future genetic testing programs in the Caribbean country.

Results from a Phase III trial presented at ASCO suggest a significant overall survival increase by adding ribociclib to endocrine therapy in HR-positive, HER2-negative breast cancer.